Paying users zone. Data is hidden behind 
.
Get 1-month access to Biogen Inc. for $15.99, or
get full access to the entire website for at least 3 months from $49.99.
We accept:
This is a one-time payment. There is no automatic renewal.
Biogen Inc. (NASDAQ:BIIB)
Analysis of Revenues
Advanced level
Revenues as Reported
Biogen Inc., Income Statement, Revenues
US$ in thousands
| 12 months ended | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Multiple Sclerosis (MS) | |||||||||||
| Spinal Muscular Atrophy | |||||||||||
| Biosimilars | |||||||||||
| Other | |||||||||||
| Hemophilia | |||||||||||
| Product revenues |
Based on: 10-K (filing date: 2020-02-06), 10-K (filing date: 2019-02-06), 10-K (filing date: 2018-02-01), 10-K (filing date: 2017-02-02), 10-K (filing date: 2016-02-03).
| Item | Description | The company |
|---|---|---|
| Product revenues | Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). | Biogen Inc.’s product revenues increased from 2017 to 2018 and from 2018 to 2019. |